The New York Times
A new drug being developed by Sanofi-Aventis extended the lives of men with advanced prostate cancer in a clinical trial and could become a new last-ditch treatment, researchers reported Wednesday.
Men whose cancer has spread beyond the prostate gland are usually treated with drugs that reduce the body’s production of testosterone, a hormone that can feed cancer growth. When such therapy fails, the only approved option now is the chemotherapy drug Taxotere, sold by Sanofi-Aventis, but that often fails as well... read more
Find a Doctor/Researcher
Make an Appointment
Refer a Patient
Make a Gift
Penn Cancer Network
